Module

Evolving Strategies for Fine-Tuning Antiretroviral Therapy: Where Have We Been, Where Are We Going?

Source: Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients With Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life

Evolving Strategies for Fine-Tuning Antiretroviral Therapy: Where Have We Been, Where Are We Going?


CME Program Director: John P. Phair, MD

Faculty:

  • William G. Powderly, MD

CME CREDIT INFORMATION

Release Date: 11/15/06

Expiration Date: 11/14/07


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.7 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe antiretroviral switch strategies designed to improve the tolerability of a virologically suppressive regimen
  • Discuss the results of clinical trials evaluating switches in antiretroviral therapy in patients with virologic suppression
  • Identify potential risks associated with regimen modification in patients with virologic suppression

Topics covered include:

  • Introduction
  • Switching for Simplification: Changing Between Drug Classes
  • Switching for Simplification: Switching Between PIs
  • Switching for Toxicity
  • Induction-Maintenance Strategies
  • Alternating Therapy and Structured Treatment Interruptions
  • Practical Implications: Fine-Tuning Antiretroviral Therapy for Success
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.